A NEW gene therapy for people suffering with Familial Amyloid Neuropathy type 1 (FAP 1), a rare genetic disease dated to the times of the Crusaders, will be offered as part of a clinical study at the Cyprus Institute of Neurology and Genetics (CING), it announced recently.